Delamanid is a critical medicine in the fight against drug-resistant tuberculosis, but its intractably high price continues to hinder access. The undersigned civil society organizations welcome the market intervention to make delamanid more affordable announced by the Clinton Health Access Initiative (CHAI) with support from Unitaid.
The WHO Global TB Program's Accelerator Platform for Novel TB Regimens held its 12th meeting to examine the four-month HPMZ (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen for tuberculosis treatment, covering country experiences, implementation tools, and next steps for rollout. Despite the World Health Organization's (WHO) 2022 recommendation, implementation has remained limited, with challenges such as high pill burden and medicine costs cited as potential barriers.
Treatment Action Group (TAG) is seeking a consultant to coordinate and strengthen the work of the Community Research Advisors Group (CRAG), one of the longest-running community advisory boards in tuberculosis (TB) research.
A landmark tuberculosis study showed that drug-sensitive TB can be treated in four months instead of six using the WHO-endorsed HPMZ regimen. This factsheet examines barriers to adoption, the role of new fixed-dose combinations, Global Fund GC8 funding opportunities, and advocacy strategies to expand access
The ASCENT DR-TB project, funded by Unitaid and led by the KNCV Tuberculosis Foundation, aims to improve access to shorter, safer and more effective treatment regimens for drug-resistant TB (DR-TB) and comprehensive, person-centered packages of quality care.
Ending HIV requires sustained research. TAG’s June 2026 cure trials update tracks clinical studies worldwide, helping advocates, researchers, and communities follow progress toward a cure.
Forty-five years ago the Centers for Disease Control and Prevention (CDC) published a brief report describing five cases of a rare pneumonia among young gay men in Los Angeles. The report occupied just a few paragraphs in the Morbidity and Mortality Weekly Report (MMWR). No one reading it could have known that it marked the beginning of one of the deadliest epidemics in modern history.
TAG and KNCV are excited to present an upcoming webinar: Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care on Tuesday, June 20, at 9 a.m. EST. This is the latest installment in the series of virtual trainings for community and civil society organizations hosted by TAG under the Unitaid-funded ASCENT DR-TB Project.
TAG and the Long-Acting Therapies Community Advisory Board (LAT CAB) welcomed a decision by the Indian Patent Office rejecting a patent application related to the hepatitis C treatment combination glecaprevir/pibrentasvir (G/P). Advocates say the decision could help reduce barriers to generic competition, lower treatment costs, and expand access to hepatitis C treatment in low- and middle-income countries disproportionately affected by the epidemic.
The Promise and Potential of Economic Reforms for Health The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid from bilateral and multilateral donors has…
Your donation will bring progress, healing, and hope — turning the promise of innovative research into a brighter, healthier future for all.
